Form 4: C4 Therapeutics Director Receives Stock Award

C4 Therapeutics, Inc. reports a director's receipt of common stock as compensation, with detailed beneficial ownership information.

Summary

• Kenneth Carl Anderson, a Director at C4 Therapeutics, Inc., received 4,259 shares of common stock on April 1, 2026.
• These shares were issued as part of the Issuer's Non-Employee Director Compensation Policy, where Mr. Anderson elected to receive stock instead of cash compensation.
• The reported price of $2.70 per share is based on the closing market price on April 1, 2026.
• Following this transaction, Mr. Anderson's direct beneficial ownership is 68,230 shares.
• Additional indirect beneficial ownership is held through various trusts: Kenneth C. Anderson 2021 Irrevocable Trust (129,877 shares), Kenneth C. Anderson 2015 Irrevocable Trust (74,581 shares), Cynthia E. Anderson 2015 Irrevocable Trust (74,581 shares), Kenneth C. Anderson Revocable Trust (3,623 shares), and Cynthia E. Anderson Revocable Trust (3,623 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation and beneficial ownership, without significant new financial or strategic information.

Positives

• Director compensation is being paid in equity, aligning director interests with shareholders.
• The company has a clear policy for compensating non-employee directors with stock awards.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that the issuance of stock awards to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to retain talent and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The issuance of stock awards to directors can be viewed positively as it aligns director compensation with company performance and shareholder interests.

Key Dates

Keywords

C4 Therapeutics, Form 4, Director Compensation, Stock Award, Beneficial Ownership, Insider Transaction, Equity Compensation